Hydrochloric Acid → 2-{4-[3-(4,6-Difluoro-1-methyl-1H-indazol-5-ylmethyl)-imidazo[1,2-b]pyridazin-6-yl]-pyrazol-1-yl}-ethanol

HRID 69288노트

반응식

HRID 69288 반응식
[F:1][C:2]1[C:10]([CH2:11][C:12]2[N:16]3[N:17]=[C:18]([C:21]4[CH:22]=[N:23][N:24]([CH2:26][CH2:27][O:28]C5CCCCO5)[CH:25]=4)[CH:19]=[CH:20][C:15]3=[N:14][CH:13]=2)=[C:9]([F:35])[CH:8]=[C:7]2[C:3]=1[CH:4]=[N:5][N:6]2[CH3:36].Cl.C([O-])(O)=O.[Na+]>O1CCOCC1>[F:1][C:2]1[C:10]([CH2:11][C:12]2[N:16]3[N:17]=[C:18]([C:21]4[CH:22]=[N:23][N:24]([CH2:26][CH2:27][OH:28])[CH:25]=4)[CH:19]=[CH:20][C:15]3=[N:14][CH:13]=2)=[C:9]([F:35])[CH:8]=[C:7]2[C:3]=1[CH:4]=[N:5][N:6]2[CH3:36]

참가 물질

5

실험 절차

To a solution of 3-(4,6-difluoro-1-methyl-1H-indazol-5-ylmethyl)-6-{1-[2-(tetrahydro-pyran-2-yloxy)-ethyl]-1H-pyrazol-4-yl}-imidazo[1,2-b]pyridazine (Stage 285.1, 30 mg, 0.061 mmol) in dioxane (2 mL) stirred at 0° C. was added a solution of HCl in dioxane (4 M, 0.152 mL). The RM was stirred 1 h at rt, poured in a solution 10% NaHCO3, and the aqueous phase was extracted with DCM. The combined organic phases were dried over MgSO4 and concentrated under reduced pressure. The residue was purified by flash chromatography (CombiFlash® Companion System®, with RediSep® silica gel column, hexane/EtOAc=100:0->80:20) to afford the title compound as a white powder (tR 3.68 min (conditions 3), MH+=410.2, 1H-NMR in DMSO-d6: 8.38 (s, 1H); 8.19 (s, 1H); 8.06 (s, 1H); 8.04 (d, 1H); 7.53-7.46 (m, 3H); 4.97 (t, 1H); 4.40 (s, 2H); 4.18 (t, 2H); 3.97 (s, 3H); 3.76 (q, 2H)).

후처리

  1. extractionthe aqueous phase was extracted with DCM
  2. dry with materialThe combined organic phases were dried over MgSO4
  3. concentrationconcentrated under reduced pressure
  4. customThe residue was purified by flash chromatography (CombiFlash® Companion System®, with RediSep® silica gel column, hexane/EtOAc=100:0->80:20)

출처 및 근거

ORD 기록
ord-963ee83d76b84ab98a1e10dbab706db1
출처 데이터셋
uspto-grants-2014_09
특허 번호
US08822468B2

반응 노트

불러오는 중…